Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001629 · ClinicalTrials.gov registry record · Phase 3
The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function
A Phase 3 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
NCT00001629 is a Phase 3 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 49 participants.
The verdict
NCT00001629, a Phase 3 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
Study Summary
The renin angiotensin system (RAS) plays an important physiological and pathophysiological role in the control of blood pressure and plasma volume. Inhibition of the RAS is useful in the treatment of hypertension, cardiac failure and in some patients with myocardial infarction. Several recent clinical trials with angiotensin converting enzyme inhibitors (ACEI) have shown that they also reduce the incidence of myocardial infarction, but the mechanisms underlying this anti-ischemic effect are poorly understood. ACEI reduce angiotensin II synthesis and prevent bradykinin degradation. Results from ongoing studies in the Cardiology Branch (Protocol 95-H-0099) designed to investigate the link between ACEI and the vascular endothelium indicate that ACEI improve both endothelial dysfunction and metabolic coronary vasodilation, an effect that is partially mediated by bradykinin. The current protocol is designed to investigate whether the beneficial effects of ACEI on endothelial function are also partly due to inhibition of angiotensin II. The recent development of selective angiotensin II type 1 (AT1) receptor antagonists allows us to specifically examine the effects of angiotensin II on vasomotor activity.
Interventions
- DRUG Angiotensin II type 1 receptor antagonists
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 1997-07 |
| Est. Completion | 2000-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001629
The ClinicalTrials.gov registry entry for NCT00001629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Angiotensin II type 1 receptor antagonists is the first listed.
NCT00001629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001629 about?
NCT00001629 is a clinical study titled "The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function". The renin angiotensin system (RAS) plays an important physiological and pathophysiological role in the control of blood pressure and plasma volume. Inhibition of the RAS is useful in the treatment of hypertension, cardiac failure and in some patients with myocardial infarction. Several recent clinic...
What is the current status of trial NCT00001629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 1997-07. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00001629?
The interventions under investigation include: Angiotensin II type 1 receptor antagonists (DRUG).
Who is sponsoring clinical trial NCT00001629?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.